Viridian Therapeutics announces common stock and preferred stock offering

Viridian Therapeutics (VRDN) announced that it has commenced an underwritten public offering of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock and Series B preferred stock, together with its cash, cash equivalents and short-term investments, to fund the company’s commercial launch activities related to veligrotug and VRDN-003 and research and development activities, as well as for working capital and general corporate purposes. Jefferies, Leerink Partners, Evercore ISI and Stifel are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as co-manager for this offering.